7 nicotinic acetylcholine receptor (nAChR) agonist (EC50
= 1.6 μ
= 260 nM at rat α
7 nAChRs). Also displays functional antagonism at histamine H3
= 103 nM) and weak agonist activity at human ganglionic α
3 nAChRs (IC50
= 8.5 μ
M). Neuroprotective in a rodent model of quisqualic acid-induced cholinergic degeneration. Brain penetrant and orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Procognitive and neuroprotective activity of a novel α7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati et al.
Consequences of linker length alteration of the α7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333.
Beinat et al.